Atyr Pharma Inc (ATYR) Stock Price, Quote & News

Company Profile

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 731 8389

Fax: 858 731 8394

Website: atyrpharma.com

Address:

10240 Sorrento Valley Road, Suite 300, San Diego, United States

Unknown_Stuntman Jul. 7 at 4:53 PM

$ATYR wild volatility today

0 · Reply

Pratik2024 Jul. 7 at 1:32 PM

$ATYR $GOOS $MWYN $PUBM $WRBY Good morning

0 · Reply

BioBingo Jul. 7 at 1:10 PM

$ATYR – What’s On This Week: Options Expiry Approaches, “Lab Conditions” Continue, and the Three-Month Countdown We’re entering the first full trading week of July, with $ATYR now within the three-month window for the pivotal Phase 3 efzofitimod readout. This week is shaping up as classic “lab conditions”: no major news, low volatility, and a calm tape post-Russell rebalance. Next short interest report drops later this week; options expiry (July 18) is fast approaching and could drive near-term positioning and volatility. Retail sentiment and engagement remain high. In my view, there’s no new info to change anyone’s core thesis—this is a period to observe, recalibrate, and prep for what’s ahead. Full long-form breakdown here: https://www.reddit.com/r/ATYR_Alpha/s/CjDzvXXBfh

0 · Reply

lola269 Jul. 7 at 12:17 PM

$IOVA $ACRV $AUTL $ATYR

0 · Reply

bob397 Jul. 5 at 3:54 PM

$ATYR

1 · Reply

bob397 Jul. 5 at 3:52 PM

$ATYR

0 · Reply

xersdave Jul. 5 at 12:54 PM

$ATYR Gimme that E-$40. SPRINKLE me.

0 · Reply

Passaten Jul. 3 at 8:10 PM

$ATYR considering how much of the shares are locked up, this stock is one of the easiest right now to “press button, get money” 😂 just gotta be careful

0 · Reply

Unknown_Stuntman Jul. 3 at 7:04 PM

$ATYR who would have thought this would turn into such a profitable day trade vehicle?

1 · Reply

RICARDO34 Jul. 3 at 4:13 PM

$ATYR under accumulation at these levels. very promising

0 · Reply

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

Jun 4, 2025, 8:00 AM EDT - 4 weeks ago

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

May 20, 2025, 8:00 AM EDT - 6 weeks ago

aTyr Pharma to Present at Upcoming Investor Conferences

May 19, 2025, 8:00 AM EDT - 7 weeks ago

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

May 16, 2025, 4:01 PM EDT - 7 weeks ago

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 14, 2025, 8:00 AM EDT - 7 weeks ago

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

May 7, 2025, 4:01 PM EDT - 2 months ago

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

Apr 29, 2025, 8:00 AM EDT - 2 months ago

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 3, 2025, 8:00 AM EDT - 3 months ago

aTyr Pharma to Participate in April Investor Conferences

Mar 26, 2025, 8:00 AM EDT - 3 months ago

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

Mar 14, 2025, 3:10 PM EDT - 4 months ago

aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating

Mar 13, 2025, 11:18 PM EDT - 4 months ago

aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:01 PM EDT - 4 months ago

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

Mar 12, 2025, 4:00 PM EDT - 4 months ago

aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine

Mar 6, 2025, 4:02 PM EST - 4 months ago

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

Mar 4, 2025, 8:00 AM EST - 4 months ago

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

Feb 24, 2025, 8:00 AM EST - 4 months ago

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

Jan 29, 2025, 8:00 AM EST - 5 months ago

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Dec 12, 2024, 4:00 PM EST - 7 months ago

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

Dec 9, 2024, 8:00 AM EST - 7 months ago

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

Nov 15, 2024, 8:00 AM EST - 8 months ago

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

Oct 24, 2024, 1:00 PM EDT - 9 months ago

aTyr Pharma: The Bull Has Finally Come Out

Oct 14, 2024, 8:00 AM EDT - 9 months ago

aTyr Pharma to Present at the LD Micro Main Event XVII in October

Sep 9, 2024, 4:37 AM EDT - 10 months ago

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

Aug 21, 2024, 8:00 AM EDT - 11 months ago

aTyr Pharma to Participate in September Investor Conferences

Aug 13, 2024, 4:00 PM EDT - 11 months ago

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

Jun 3, 2024, 8:00 AM EDT - 1 year ago

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”

May 15, 2024, 7:00 AM EDT - 1 year ago

aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

May 2, 2024, 4:00 PM EDT - 1 year ago

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

Mar 14, 2024, 11:37 PM EDT - 1 year ago

aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 4:00 PM EDT - 1 year ago

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

Feb 28, 2024, 8:00 AM EST - 1 year ago

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

Feb 21, 2024, 8:00 AM EST - 1 year ago

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants

Jan 18, 2024, 8:00 AM EST - 1 year ago

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

Nov 13, 2023, 8:00 AM EST - 1 year ago

aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023

Nov 1, 2023, 8:00 AM EDT - 1 year ago

aTyr Pharma to Present at November Investor Conferences

Sep 11, 2023, 8:00 AM EDT - 1 year ago

aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes

Aug 24, 2023, 8:00 AM EDT - 2 years ago

aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 9, 2023, 4:00 PM EDT - 2 years ago

aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update

Jun 20, 2023, 8:00 AM EDT - 2 years ago

aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference

May 25, 2023, 8:00 AM EDT - 2 years ago

aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference

May 11, 2023, 4:00 PM EDT - 2 years ago

aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference

May 9, 2023, 4:00 PM EDT - 2 years ago

aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update

Mar 20, 2023, 8:00 AM EDT - 2 years ago

aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies

Mar 10, 2023, 5:12 PM EST - 2 years ago

aTyr Pharma, Inc. (LIFE) Q4 2022 Earnings Call Transcript

Mar 9, 2023, 4:00 PM EST - 2 years ago

aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Mar 8, 2023, 8:00 AM EST - 2 years ago

aTyr Pharma to Present at March Investor Conferences

Feb 8, 2023, 4:11 PM EST - 2 years ago

aTyr Pharma Announces Commencement of Public Offering of Common Stock

Jan 19, 2023, 8:00 AM EST - 2 years ago

aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis

Unknown_Stuntman Jul. 7 at 4:53 PM

$ATYR wild volatility today

0 · Reply

Pratik2024 Jul. 7 at 1:32 PM

$ATYR $GOOS $MWYN $PUBM $WRBY Good morning

0 · Reply

BioBingo Jul. 7 at 1:10 PM

0 · Reply

lola269 Jul. 7 at 12:17 PM

$IOVA $ACRV $AUTL $ATYR

0 · Reply

bob397 Jul. 5 at 3:54 PM

$ATYR

1 · Reply

bob397 Jul. 5 at 3:52 PM

$ATYR

0 · Reply

xersdave Jul. 5 at 12:54 PM

$ATYR Gimme that E-$40. SPRINKLE me.

0 · Reply

Passaten Jul. 3 at 8:10 PM

$ATYR considering how much of the shares are locked up, this stock is one of the easiest right now to “press button, get money” 😂 just gotta be careful

0 · Reply

Unknown_Stuntman Jul. 3 at 7:04 PM

$ATYR who would have thought this would turn into such a profitable day trade vehicle?

1 · Reply

RICARDO34 Jul. 3 at 4:13 PM

$ATYR under accumulation at these levels. very promising

0 · Reply

xersdave Jul. 3 at 12:17 PM

$ATYR Spread the word to your homies. Let’s get this MF STACKED.

1 · Reply

DonCorleone77 Jul. 3 at 10:53 AM

$ATYR Information regarding Wells Fargo analyst report on ATYR issued today: https://x.com/CorleoneDon77/status/1940723846606184950

1 · Reply

Pratik2024 Jul. 2 at 8:28 PM

$ATYR $GOOS $MWYN $PUBM $WRBY MWYN $1.64 to $2.3 last week, then back to $1.64!! Loading time for another biggy move.

0 · Reply

OriginalTradeonrumor Jul. 2 at 7:00 PM

$ATYR as I explicitly stated, we will be jn this consolidated range of upper 4’s to 5.30’s for a bit and no surprise here we been🙂 While we wait for a surge higher out of this range ( which IMO will come prior to readout)…it amazes me how some people who supposedly have a bunch of money tied up here are trying to search for solice in posts If you have significant money in this or any stock you better have done a hell of a lot of homework way beyond posts! Anyway..not my circus not my clowns 😁 With that said Bio thanks for the informative posts …they are teaching a ton of people about market dynamics ..valuable stuff For all ….buy on the dips and hold for the surge!🙂 Let’s see what happens!

1 · Reply

Woodpecker99 Jul. 2 at 3:27 PM

$ATYR this thing doesn’t move much huh

6 · Reply

Lloyd03 Jul. 2 at 2:21 PM

$ATYR

0 · Reply

__Godzilla__ Jun. 30 at 9:03 PM

$ATYR I am bullish on ATYR, but a couple of related thoughts. 1) The fact that any company (not picking on ATYR here) can be added to the Russell 2000 and Russell 3000 before it has shown to have a viable product is absurd. I know that both indexes are cap weighted and ATYR's affect is miniscule, but ATYR's inclusion is premature. 2) ATYR's inclusion means it joins the 40% of R2000 companies that won't make a profit in 2025. If you need a good reason not to own a R2000 or R3000 index fund or index ETF, then this is it. I would rather pay an active manager to select companies that make money than own the 40% that don't.

4 · Reply

BioBingo Jun. 30 at 8:06 PM

$ATYR – Cantor Roadshow Announced for July 30–31: Reading Between the Lines https://www.reddit.com/r/ATYR_Alpha/s/fSJVI2WWdB Cantor Fitzgerald will host a two-day Non-Deal Roadshow with aTyr Pharma ($ATYR) on July 30 (Denver, in-person) and July 31 (virtual), featuring CEO Sanjay Shukla and CFO Jill Broadfoot. On its surface, this might seem like standard IR. But the timing — which coincides with the listed primary completion date for aTyr’s Phase 3 trial — strongly suggests management has already seen the top-line data and is moving proactively to frame the story for institutions. This isn’t just a check-in. It’s likely a strategic narrative move: prepping key funds ahead of the readout and shaping how the results will be interpreted. If you’re watching $ATYR, this is worth your attention. Full analysis at the link.

2 · Reply

Hereinbama35 Jun. 30 at 4:09 PM

$ATYR This girl is playing with my feelings.

2 · Reply

BioBingo Jun. 30 at 12:18 PM

$ATYR – What’s On This Week: Post-Expiry Flows, Russell Rebalance, and Structural Positioning Just dropped an update for this week’s $ATYR setup, with a focus on what’s happening after the Russell rebalance, the latest options expiry, and why market structure matters so much right now. With no big catalysts, earnings, or filings on deck, we’re entering one of the quietest stretches in a while—prime time to observe tape behavior, track block trades, and spot any stealthy accumulation. I also share some new stats from my ongoing analysis of all 126 new Russell additions, plus details about the upcoming biotech training series for anyone wanting to level up. Community just hit 750+ members in under 7 weeks—appreciate the support! Full post here: https://www.reddit.com/r/ATYR_Alpha/s/MT4w9GVRGl

0 · Reply

Passaten Jun. 30 at 2:49 AM

$ATYR TO THE MOON

0 · Reply

BioBingo Jun. 30 at 1:11 AM

$ATYR - The Russell Index Rebalance: The Game Behind the Game Friday 27 June was the wildest day yet for $ATYR: nearly 15.7M shares traded as it joined the Russell 2000 & 3000, yet the price barely moved. How does that happen when trillions in assets have to buy? It’s not just about volume—it’s about who’s really in control. I break down exactly how indexers, arbs, market makers, and shorts orchestrate these moves, why retail gets whipsawed, and what it means for future price action. The float is tighter, the game has changed, and if you want to level up as a retail investor, understanding the mechanics is now non-negotiable. Full deep-dive here: https://www.reddit.com/r/ATYR_Alpha/s/LXmQSF0K75

0 · Reply

Market Cap	472.61M
Revenue (ttm)	240,000.00
Net Income (ttm)	-64.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-26,675.00%
Debt to Equity Ratio	0.00

Volume	2,294,876
Avg Vol	2,388,266
Day's Range	N/A - N/A
Shares Out	89.00M
Stochastic %K	74%
Beta	0.89
Analysts	Strong Sell
Price Target	$20.17